Cargando…
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
PURPOSE: ATI-450 is an oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase (MAPK)/MAPK-activated protein kinase 2 (MK2) inflammatory signaling pathway. This phase 1, single and multiple ascending dose (SAD, MAD) study evaluated ATI-450 safety, tolerability, pharmacokinetics,...
Autores principales: | Gordon, David, Hellriegel, Edward T, Hope, Heidi Rath, Burt, David, Monahan, Joseph B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203602/ https://www.ncbi.nlm.nih.gov/pubmed/34140814 http://dx.doi.org/10.2147/CPAA.S305308 |
Ejemplares similares
-
605. Efficacy and pharmacokinetics-pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D, et al.
Publicado: (2022) -
Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D., et al.
Publicado: (2023) -
Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis
por: Gordon, David, et al.
Publicado: (2023) -
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020) -
Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)